Skip to content

Acceptance and Commitment Therapy and Risperidone in Obsessive-Compulsive Disorder

A comparative study on the efficacy of Acceptance and Commitment Therapy(ACT) and Risperidone in treatment of children with Obsessive-Compulsive Disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20241013063349N1
Enrollment
30
Registered
2024-11-09
Start date
2023-06-15
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: Prescription of Risperidone manufactured by Poursina Pharmaceutical Company with an average dose of 1 mg per day for 12 weeks. Intervention 2: Intervention group: C

Sponsors

Kashan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 12 Years

Inclusion criteria

Inclusion criteria: Age between 7 to 12 years Yale-Brown Obsessive-compulsive Rating scale greater or equal to 16 A diagnosis of Obsessive-Compulsive Disorder according to DSM-5 criteria by a child and adolescent psychiatrist

Exclusion criteria

Exclusion criteria: Diagnosis of psychotic disorders Diagnosis of bipolar disorder Diagnosis of autism spectrum disorders Diagnosis of intellectual disabilities Any medical condition in which risperidone is contraindicated Any current psychotherapy

Design outcomes

Primary

MeasureTime frame
Yale-Brown Obsessive-Compulsive Scale Score. Timepoint: At the beginning of the study (before the start of the intervention) and weeks 2, 4, 8 and 12 after the intervention. Method of measurement: Yale-Brown Obsessive- Compulsive Questionnaire.

Secondary

MeasureTime frame
Change in Y-BOCS score based on the duration of illness in children. Timepoint: Baseline (week 0), week 2, week 4, week 8, and week 12. Method of measurement: Y-BOCS score categorized by illness duration at each timepoint.;Change in Y-BOCS score across different age groups of children. Timepoint: Baseline (week 0), week 2, week 4, week 8, and week 12. Method of measurement: Y-BOCS scores analyzed by age groups at each timepoint.;Gender-based comparison of Y-BOCS score changes in children. Timepoint: Baseline (week 0), week 2, week 4, week 8, and week 12. Method of measurement: Y-BOCS scores assessed and compared by gender at each timepoint.;Reduction in compulsive behavior score within the Y-BOCS, specifically addressing time spent on obsessive thoughts and the extent of distress caused. Timepoint: Baseline (week 0), week 2, week 4, week 8, and week 12. Method of measurement: Y-BOCS subscale specific to compulsive behavior dimensions, focusing on time, distress level, and interference with daily life.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFada Tolouee

Kashan University of Medical Sciences

fada.gp1373@gmail.com+98 31 5558 9213

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026